Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.57 |
| ▸ | CA2 | P00918 | 8/20 | 0.57 |
| ▸ | CA12 | O43570 | 5/20 | 0.57 |
| ▸ | CA9 | Q16790 | 5/20 | 0.57 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16344311 | 1.00 | CA1 (0.57) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL910539 | 0.93 | CA1 (0.62) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL16383769 | 0.91 | CA1 (0.57) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17809681 | 0.91 | CA1 (0.53) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17809675 | 0.91 | CA1 (0.53) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL16383753 | 0.90 | MAPK1 (0.57) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17919114 | 0.90 | MAPK1 (0.57) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17809668 | 0.89 | CA1 (0.55) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL17919110 | 0.89 | CA1 (0.55) | CA1CA2CA12CA9SUCNR1 | |
| SCHEMBL2328368 | 0.86 | CA1 (0.61) | CA1CA2CA12CA9SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656972-B2 | Compounds for treatment of cystic fibrosis | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-05-23 | — | — | US | disclosed |
| WO-2016112120-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-07-14 | — | — | WO | disclosed |
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2016-06-09 | — | — | US | disclosed |
| WO-2015003083-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159754-A1 | COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, ELANE, OTC | CA1 4834/4885CA2 2965/4885CA12 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.